6-p-tolyl-3,4-dihydronaphthalen-2(1H)-one | 1062649-18-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-p-tolyl-3,4-dihydronaphthalen-2(1H)-one
• 英文别名: 6-(4-methylphenyl)-3,4-dihydro-1H-naphthalen-2-one
• CAS: 1062649-18-6
• 化学式: C₁₇H₁₆O
• 分子量: 236.313
• InChiKey: MEPYYVPVGNWMJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-p-tolyl-3,4-dihydronaphthalen-2(1H)-one 在 sodium hydride 、 溶剂黄146 作用下， 反应 2.0h， 生成 2-pyridin-2-yl-7-p-tolyl-4,5-dihydro-2H-benzo[e]indazol-1-ol
  参考文献：
  名称：

  Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1)

  摘要：

  Three distinct series of substituted pyrazole blockers of divalent metal transporter 1 (DMT1) were elaborated from the high-throughput screening pyrazolone hit 1. Preliminary hit-to-lead efforts revealed a preference for electron-withdrawing substituents in the 4-amido-5-hydroxypyrazole series 6a-l. In turn, this preference was more pronounced in a series of 4-aryl-5-hydroxypyrazoles 8a-j. The representative analogs 6f and 12f were found to be efficacious in a rodent model of acute iron hyperabsorption. These three series represent promising starting points for lead optimization efforts aimed at the discovery of DMT1 blockers as iron overload therapeutics. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.069
• 作为产物：
  描述：

  6-溴-2-四氢萘酮 、 4-甲苯硼酸 在 palladium diacetate 四丁基溴化铵 、 sodium carbonate 作用下， 以 水 为溶剂， 反应 0.12h， 以51%的产率得到6-p-tolyl-3,4-dihydronaphthalen-2(1H)-one
  参考文献：
  名称：

  DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS

  摘要：

  本发明涉及具有以下结构式(I)的化合物：其中m、R1、R2、R3和R4如本文所定义，作为其立体异构体、对映体、互变异构体或其混合物；或其药学上可接受的盐、溶剂合物或前药，用于治疗铁相关疾病。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗铁相关疾病的方法。

  公开号：

  US20080234327A1

文献信息

• [EN] DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS<br/>[FR] COMPOSÉS À BASE DE DIHYDROINDAZOLE UTILES DANS LE TRAITEMENT DES TROUBLES DU MÉTABOLISME DU FER
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2008118790A1

  公开（公告）日：2008-10-02

  [EN] This invention is directed to compounds of formula (I): wherein formula (A), m, R¹, R², R³ and R⁴ are are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.
  [FR] L'invention concerne des composés de formule (I) où la formule (A), R¹, R², R³ et R⁴ sont tels que définis dans la description, tels qu'un de leurs stéreoisomères, nantiomères, tautomères ou un de leurs mélanges; ou un de leurs sels pharmaceutiquement acceptables, solvates ou promédicaments, destinés à traiter les troubles du métabolisme du fer. L'invention concerne également des compositions pharmaceutiques renfermant ces composés et des procédés d'utilisation de ces composés pour traiter les troubles du métabolisme du fer.
• DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS
  申请人：Cadieux Jean-Jacques

  公开号：US20080234327A1

  公开（公告）日：2008-09-25

  This invention is directed to compounds of formula (I): wherein m, R 1 , R 2 , R 3 and R 4 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

  本发明涉及具有以下结构式(I)的化合物：其中m、R1、R2、R3和R4如本文所定义，作为其立体异构体、对映体、互变异构体或其混合物；或其药学上可接受的盐、溶剂合物或前药，用于治疗铁相关疾病。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗铁相关疾病的方法。
• Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1)
  作者：Jay A. Cadieux、Zaihui Zhang、Maryanne Mattice、Alison Brownlie-Cutts、Jianmin Fu、Laszlo G. Ratkay、Rainbow Kwan、Jay Thompson、Joseph Sanghara、Jing Zhong、Y. Paul Goldberg

  DOI：10.1016/j.bmcl.2011.11.069

  日期：2012.1

  Three distinct series of substituted pyrazole blockers of divalent metal transporter 1 (DMT1) were elaborated from the high-throughput screening pyrazolone hit 1. Preliminary hit-to-lead efforts revealed a preference for electron-withdrawing substituents in the 4-amido-5-hydroxypyrazole series 6a-l. In turn, this preference was more pronounced in a series of 4-aryl-5-hydroxypyrazoles 8a-j. The representative analogs 6f and 12f were found to be efficacious in a rodent model of acute iron hyperabsorption. These three series represent promising starting points for lead optimization efforts aimed at the discovery of DMT1 blockers as iron overload therapeutics. (C) 2011 Elsevier Ltd. All rights reserved.